Olivia Newton-John Cancer Research Institute embarks on technology overhaul with Hewlett Packard Enterprise to accelerate cancer research capabilities

March 12, 2025

HPE Alletra Storage provides a future-ready data solution, delivering innovation agility to support cutting-edge cancer research and improve patient outcomes.


Melbourne, Australia – 12 March 2025Hewlett Packard Enterprise (NYSE: HPE) today announced a collaboration with the Olivia Newton-John Cancer Research Institute (ONJCRI) to modernize and elevate the institute's operations. Leveraging HPE Alletra Storage MP B10000 and HPE Alletra Storage Server 4000 with Qumulo, the collaboration aims to transform ONJCRI’s operations. Working to enhance capacity and performance of infrastructure, the collaboration supports cutting-edge cancer research, accelerated treatment breakthroughs, and improvement in patient outcomes.

Based in Melbourne, Australia, ONJCRI is a leading medical research organization dedicated to advancing cancer understanding and treatment through innovative research. By adopting HPE Alletra Storage solutions, ONJCRI is optimizing its operational capabilities, enabling dynamic resource scaling to meet evolving research demands. A modern data solution must support both structured data and unstructured data. The solution from HPE unlocks the value in both by significantly reducing infrastructure scaling lead times, empowering the institute to accelerate its groundbreaking work in cancer research and treatment.

“The fast pace of cancer research demands highly responsive and adaptable IT infrastructure”

Dr Christine De Nardo
Chief Operating Officer of the Olivia Newton-John Cancer Research Institute

"The fast pace of cancer research demands highly responsive and adaptable IT infrastructure to support our mission of improving patient outcomes," said Dr Christine De Nardo, Chief Operating Officer of the Olivia Newton-John Cancer Research Institute. As a result of the implementation, ONJCRI can now expand its collaboration options between Australian and global research partners, including the secure transfer of large data sets, fostering seamless collaboration and knowledge sharing on a global scale – working to develop cancer treatments that are more effective, tolerable and accessible for all patients.

Additionally, the upgraded infrastructure supports advanced AI-driven applications, which unlocks possibilities such as analyzing historical data – like patient samples – at an unprecedented scale, modeling tumor types to predict response to treatment, likely side effects and survival rates, or applying algorithms to known therapies to predict treatment effectiveness.

"Operationally, our goal is to achieve greater efficiency, scalability, and flexibility to keep pace with the evolving needs of our research and the broader industry. HPE has been a key enabler, connecting us with the tools and strategic partnerships necessary to optimize our operations and accelerate the breakthroughs that make a real difference in patients' lives" continued Dr De Nardo.

The combination of HPE Alletra Storage MP B10000 and HPE Alletra Storage Server 4000 with Qumulo solutions is significantly enhancing ONJCRI’s operational efficiency, enabling the institute to discover and develop breakthrough cancer therapies to provide the best health outcomes for patients.

“Collaboration with the Olivia Newton-John Cancer Research Institute is a powerful example of how HPE Solutions can transform the medical research landscape”

Chris Weber
Vice President and Managing Director, South Pacific at Hewlett Packard Enterprise

Chris Weber, Vice President and Managing Director, South Pacific at Hewlett Packard Enterprise, commented on the importance of the partnership, “Our collaboration with the Olivia Newton-John Cancer Research Institute is a powerful example of how HPE Solutions can transform the medical research landscape, enhancing operational efficiencies and ensuring critical resources – such as research centers – can keep pace with innovation and advanced research to improve patient outcomes."

Share this article